GlassScriptPhysician profile
Donna V Wall
NPI 1184603045
$9,445.15
in general payments reported to CMS, 2019-2025
56 companies · $2,988 in 2025
The $2,988 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $1,734 · 2023: $1,583 · 2024: $2,841 · 2025: $2,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,036 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,035.94 |
| Education | $376.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $740.70 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $679.50 | 2022-2025 | Tagrisso, Lynparza, Enhertu |
| Pfizer INC. | $523.36 | 2021-2025 | |
| Abbvie INC. | $482.18 | 2024-2025 | |
| Daiichi Sankyo INC. | $476.98 | 2022-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $432.68 | 2022-2025 | Imbruvica, Darzalex, Erleada |
| Merck Sharp & Dohme LLC | $425.18 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $409.77 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Sobi, INC | $372.34 | 2022-2025 | |
| Incyte Corporation | $299.41 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $293.48 | 2022-2025 | |
| Genentech USA, INC. | $293.39 | 2022-2025 | Polivy, Tecentriq, Lunsumio |
| E.R. Squibb & Sons, L.L.C. | $271.21 | 2022-2025 | Opdivo, Opdualag |
| Eisai INC. | $260.76 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $231.14 | 2021-2025 | Libtayo |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $225.57 | 2022-2025 | |
| Gilead Sciences, INC. | $224.82 | 2022-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $209.08 | 2022-2025 | Alunbrig, Iclusig, Ninlaro |
| Jazz Pharmaceuticals INC. | $197.10 | 2022-2025 | |
| Glaxosmithkline, LLC. | $196.21 | 2022-2025 | Ojjaara, Blenrep, Shingrix |
| Amgen INC. | $172.66 | 2021-2022 | |
| Celgene Corporation | $137.18 | 2022-2023 | Pomalyst |
| Puma Biotechnology, INC. | $127.53 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $117.62 | 2022-2025 | Xpovio |
| Deciphera Pharmaceuticals INC. | $110.97 | 2022-2025 | Qinlock, Romvimza, Tgct |
| Stemline Therapeutics INC. | $107.61 | 2024-2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $105.86 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacyclics LLC, An Abbvie Company | $105.85 | 2022-2023 | Imbruvica |
| Coherus Oncology, INC. | $92.11 | 2022-2025 | Loqtorzi |
| Pharmaessentia USA Corporation | $91.82 | 2024-2025 | Besremi |
| Sanofi-Aventis U.S. LLC | $81.99 | 2022 | |
| Array Biopharma INC | $80.90 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Exelixis INC. | $72.43 | 2024-2025 | Cabometyx |
| Lilly USA, LLC | $72.22 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Alexion Pharmaceuticals, INC. | $70.24 | 2022-2025 | Ultomiris |
| Astellas Pharma US INC | $67.27 | 2024 | Xtandi, Padcev |
| Agios Pharmaceuticals, INC. | $61.21 | 2024-2025 | Pyrukynd |
| Beigene USA, INC. | $52.43 | 2024-2025 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $48.53 | 2022 | |
| Beone Medicines USA, INC. | $44.83 | 2025 | Brukinsa, Tevimbra |
| Epizyme, INC. | $37.49 | 2022 | |
| G1 Therapeutics, INC. | $36.14 | 2023 | Cosela |
| Taiho Oncology, INC. | $34.71 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.46 | 2023 | Gilotrif |
| Servier Pharmaceuticals LLC | $29.93 | 2025 | |
| Tersera Therapeutics LLC | $27.87 | 2024 | Zoladex |
| Blueprint Medicines Corporation | $24.15 | 2022 | |
| Sumitomo Pharma America, INC. | $23.28 | 2025 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $22.10 | 2024 | Cosela |
| Emd Serono, INC. | $21.62 | 2025 | |
| Aveo Pharmaceuticals, INC. | $18.84 | 2024 | |
| Adaptive Biotechnologies Corporation | $16.71 | 2024 | Clonoseq |
| Biomarin Pharmaceutical INC. | $13.98 | 2023 | Roctavian |
| Cti Biopharma Corp. | $13.71 | 2023 | Vonjo |
| Mirati Therapeutics, INC. | $13.67 | 2024 | Krazati |
| Janssen Pharmaceuticals, INC | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.